Skip to Main Content
Contribute Try STAT+ Today

The results of a new study are re-igniting a debate among cardiologists as to whether a prescription fish oil product, Vascepa, reduces patients’ risk of heart attacks and strokes.

The study doesn’t test Vascepa, made by Amarin Corp., but another drug called Epanova, which is made by AstraZeneca. But this new trial, called STRENGTH and presented Sunday at the virtual meeting of the American Heart Association, was completely negative, while an earlier trial of Vascepa, called REDUCE-IT, showed that Vascepa reduces heart attack, stroke, and cardiovascular death by 25%. When a Food and Drug Administration panel voted on whether to give Vascepa a broader approval last year, the vote was unanimous. So many cardiologists are struggling to figure out, what gives?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.